BioCentury
ARTICLE | Finance

Venturing to share

Why Abingworth's new fund is solely focused on risk-sharing deals

January 25, 2016 8:00 AM UTC

Abingworth has seen enough success with its clinical risk-sharing investments that it opted to raise a fund dedicated solely to finding more. Last week, the firm closed its Abingworth Clinical Co-Development fund at $105 million.

In prior funds, a portion of Abingworth's investments went to a pair of risk-sharing entities - SFJ Pharmaceuticals Inc. and Avillion LLP. Both companies are agnostic to therapeutic area and partner with pharmas to run late-stage studies of pharma-owned molecules. The risk-sharing companies pay for clinical and regulatory expenses and are eligible for payments if the compound is approved...